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ABSTRACT 
Chronic obstructive pulmonary disease (COPD), a common 
preventable and treatable disease, is characterized by persistent 
airflow limitation that is usually progressive and associated with 
an enhanced chronic inflammatory response in the airways and 
the lung to noxious particles or gases. Clinical diagnosis of COPD 
should be considered in any individual, who has dyspnea, chronic 
cough, sputum production, and positive history of risk factors. 
Pharmacologic therapy can reduce COPD symptoms, reduce 
the frequency and severity of exacerbations, and improve health 
status and exercise tolerance. After cessation of smoking and 
life style modification, bronchodilator therapy is the first step in 
COPD treatment. Beside commonly used bronchodilator therapy 
newly developed bronchodilators started to be preferred. These 
drugs consist of long-acting beta2 agonist (Indacatarol, Vilanterol, 
Olodaterol, Abediterol), long acting muscarinic antagonism 
(Umeclidinium), long-acting beta2 agonist with inhaled steroid 
(combination of fluticasone furoate and vilanterol), long-acting 
beta2 agonist with a long-acting muscarinic antagonist (Fixed-
dose combination of indacaterol with glycopyrronium by means of 
breezhaler device). 
Keywords: Pulmonary disease, Chronic obstructive, 
Bronchodilator agents
Introduction 
Chronic Obstructive Pulmonary Disease (COPD), a common 
preventable and treatable disease, is characterized by 
persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response 
in the airways and the lung to noxious particles or gases 
[1]. Prevalence, morbidity and mortality of COPD vary 
across countries and different groups in the same country 
[2]. Prevalence of COPD is higher in male population in 
urban areas and the leading cause is tobacco smoking; on 
the other hand it is higher in female population in rural areas 
and the leading cause is biomass exposure [3]. Clinical 
diagnosis of COPD should be considered in any individual, 
who has dyspnea, chronic cough, sputum production, and 
positive history of risk factors [1]. This clinical context plus 
spirometric result (post-bronchodilator forced expiratory 
volume in 1 second (FEV1) to force vital capacity (FVC) 
ratio %70) confirms the diagnosis of COPD4. Next step is 
the classification of the disease according to the severity 
of airflow limitation. The goal of COPD assessment is 
determining the severity of disease in order to guide the 
treatment [4]. Besides the severity of airflow limitations 
people classified according to their risk of hospitalization 
and severity of symptoms. Patient Group A: Low Risk, Less 
Symptoms, Group B: Low Risk, More Symptoms, Group C: 
High Risk, Less Symptoms, and Group D: High Risk, More 
Symptoms.
Steps of COPD treatment 
•	 Smoking cessation; pharmacotherapy and nicotine 
replacement 
•	 Pharmacologic therapy can reduce COPD symptoms, 
reduce the frequency and severity of exacerbations, and 
improve health status and exercise tolerance.
•	 Pharmacological treatment needs to be patient-specific; 
New bronchodilators in treatment of chronic obstructive pulmonary 
disease
Baran Balcan
Department of Pulmonary Medicine, School of Medicine, Başkent 
University, Ankara, Turkey
e-mail: baranb@baskent-ist.edu.tr
Baran BALCAN
24 Balcan
New bronchodilators in treatment of COPD Marmara Medical Journal 2016; 29 (Special issue 2): 23-25
guided by severity of symptoms, risk of exacerbations, 
drug availability, and the patient’s response. 
•	 Influenza and pneumococcal vaccination should be 
offered to every COPD patient. 
•	 Non-surgical bronchoscopic lung volume reduction 
techniques 
Pharmacotherapy
•	 Bronchodilators 
o Long acting ß2 agonist and anticholinergics are 
preferred to short acting ones.
o If symptoms are not improved with single agents, 
combination therapies should be considered.
o Inhaled bronchodilators are preferred to oral agents.
•	 Corticosteroids
o Long term inhaled corticosteroid treatment is preferred 
in patients who has severe airflow limitation, and in 
patients who has frequent exacerbations despite use 
of long acting ß2 agonist.
o Long term monotherapy with oral steroids is not 
recommended 
o Long term single inhaled corticosteroid therapy is not 
recommended, instead combination with long acting 
ß2 agonist with inhaled steroid is preferred.
Newly developed bronchodilators
Long-acting beta2 agonist (LABA)
Indacaterol, is a novel, once daily used, long acting beta2 
agonist drug. Potency of this molecule is not as effective 
as formoterol or salmeterol but its potency is more than 
albuterol. It quickly onsets its bronchodilation action, and 
it has a longer duration of action when compared with these 
three molecules. One important advantage of indacaterol is 
once daily use due to its longer duration of action [5]. It 
has not more side effects on cardiovascular, or respiratory 
system, when compared to other LABAs [6]. 
Vilanterol (GW642444), a novel LABA used via 
inhalation [7]. In a randomized placebo controlled study 602 
COPD patients were evaluated. Patients were randomized 
(double-blind)	 to	 vilanterol	 3,	 6.25,	 12.5,	 25,	 or	 50	 μg	 or	
placebo once daily for 28 days. At the end of the 4th week, 
improvement in the pulmonary functions is dose dependent 
and	vilanterol	25,	or	50μg	 leads	 to	 statistically	 significant	
improvement in FEV1 values [8]. 
Olodaterol (BI1744CL) is a novel, once-daily used LABA 
developed	 with	 the	 aim	 of	 improving	 β2-adrenoreceptor	
selectivity and intrinsic activity. Phase III pivotal trials have 
documented	that	olodaterol	Respimat	Soft	Mist	inhaler	5μg	
induces fast onset of bronchodilation, comparable with 
formoterol at day 1. Moreover, significant lung function 
improvements have been documented up to 48 weeks in 
patients with moderate to very severe COPD [9]. 
Abediterol is a different LABA which was compared 
with other LABAs et including indacaterol, olodaterol, 
vilanterol in vivo by Aparici. Abediterol has higher potency 
than other molecules in bronchodilation, its half life is longer 
than vilanterol but less than indacaterol and olodaterol [10]. 
All these novel drugs are alternative treatments in especially 
early stages of COPD. 
Long acting muscarinic antagonism (LAMA) 
Umeclidinium, a blocker of muscarinic subtype (M3) 
receptor, decreases the airway tone and improves the lung 
function. This molecule was compared with thiotropium 
in vivo, and it was shown that it blocked Ach-induced 
bronchoconstriction with longer duration of action. They 
suggest that umeclidinium can be used once a daily in the 
treatment of COPD [11]. 
These novel treatment options can be used especially in 
early stages of COPD, but better clinical outcomes can be 
achieved with combination of LABA with inhaler steroid, or 
combination of LABA with LAMA.
Long-acting beta2 agonist with inhaled steroid 
Available inhaled corticosteroid/LABA combinations for 
COPD require twice-daily administration. The combination 
of fluticasone furoate (FF) and vilanterol (VI) is being 
developed in a novel dry powder inhaler for the treatment 
of COPD with the potential for once-daily dosing. Boscia 
et al compared outcomes in COPD patients; one group 
used FF/VI combination, and the other group used placebo. 
Results have shown clinically and statistically significant 
improvements over placebo in FEV1, and there was a 
significant improvement in pulmonary functions test results 
[12]. 
Combining a LABA with a LAMA
Fixed-dose combination of indacaterol 110 µg/
glycopyrronium 50 µg by means of breezhaler device 
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(QVA149) has been shown in a series of clinical trials to 
be as safe as the single components and placebo, and more 
effective than placebo and the single components with 
regard to lung function, symptoms, and patient-oriented 
outcomes [13]. In addition it has better outcomes in both 
pulmonary functions and clinical outcomes of patients 
when compared to twice daily salmeterol and fluticazone 
combination [13]. The ENLIGHTEN study compared 
QVA149 with placebo; there was satisfactory improvement 
of FEV1, most of patients reporting no daytime symptoms, 
they were able to perform usual daily activities, and they 
did not report night-time awakenings [14]. In SHINE study 
they compared QVA149 with not only placebo but also with 
thiotropium handihaler 18 µg. Similar to ENLIGHTEN 
study better outcomes achieved in improvement of FEV1, 
and symptoms of patients [15]. In ILLUMINATI study 
they compared QVA149 with salmeterol 50 µg/fluticasone 
500 µg. In QVA149 group better spirometric results were 
achieved, but there was no difference between clinical 
outcome and improvement of symptoms [16].
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